Several small biotechs working on new treatments for weight loss believe that developing therapies with mechanism of actions not seen with current drugs, such as those from Novo Nordisk (NVO) and Eli ...

Founded in 1935 by Khwaja Abdul Ahmeid, Cipla operates through two segments: Pharmaceuticals and New Ventures. Cipla Limited specialises in developing medications, primarily treating respiratory ...

Wedbush restated their outperform rating on shares of Scholar Rock (NASDAQ:SRRK – Free Report) in a research note published on Wednesday,RTT News reports. They currently have a $47.00 target price on ...

A closing highlight of the programme is the joint symposium for all European Amgen Scholars in Cambridge, UK. In addition to conducting hands-on research, you will attend workshops and events offering ...

CAMBRIDGE, Mass., January 29, 2025--Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic ...

Scholar Rock is asking the U.S. Food and Drug Administration (FDA) to approve apitegromab, its experimental add-on therapy designed to boost motor function in people with spinal muscular atrophy (SMA) ...

Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company, has appointed Lisa Wyman as the Chief Technical and ...

Scholar Rock has done well to advance its anti-myostatin ... who runs the Biotech Analysis Central pharmaceutical service on Seeking Alpha Marketplace. If you like what you read here and would ...

CAMBRIDGE, Mass. - Scholar Rock (NASDAQ: SRRK), a biopharmaceutical company with a market capitalization of $3.96 billion and an impressive 362.73% stock price surge over the past six months, ...